Hair loss treatments like finasteride, minoxidil, and hair transplants have side effects and limitations. There is hope for future advancements in stemcell therapy and hairfollicle regeneration, though skepticism about their effectiveness and timeline persists.
Pelage is developing a topical hairfolliclestemcell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
HairClone is developing cell replacement treatments to rejuvenate and generate hairfollicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
Hair loss involves more than just DHT, with genetic factors like TRPS affecting hairfollicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.